WallStreetZenWallStreetZen

NASDAQ: SPRO
Spero Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Spero Therapeutics earnings were $7.4M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest SPRO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$9.6M, up 32.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SPRO reported annual earnings of $8.6M, with -112.5% growth. The next SPRO earnings date is Nov 12, 2026.

SPRO past earnings growth

How has SPRO's earnings growth performed historically?

Company
N/A
Industry
18.22%
Market
91.74%
SPRO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
SPRO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

SPRO earnings history

Current Revenue
$47.0M
Current Earnings
$7.4M
Current Profit Margin
15.7%

SPRO Return on Equity

Current Company
16.2%
Current Industry
-10.8%
Current Market
30.9%
SPRO's Return on Equity (16.2%)... subscribe to Premium to read more.
High Return on Equity Performance

SPRO Return on Assets

Current Company
12.6%
Current Industry
-10.7%
SPRO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when SPRO announces earnings.

SPRO Return on Capital Employed

Current Company
17.24%
Current Industry
-7.4%
SPRO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SPRO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
SPRO$7.64M$7.38M+55.03%$0.14
PMVP-$75.08M-$75.22MN/A-$1.42
OKYO-$8.50M-$8.95MN/A-$0.24
ALDX-$21.37M-$23.05MN/A-$0.38
MAIA-$26.85M-$26.85MN/A-$0.62
View Top Biotech Stocks

SPRO earnings dates

Next earnings date
Nov 12, 2026

Spero Therapeutics Earnings Reports & History FAQ

What were Spero Therapeutics's earnings last quarter?

On SPRO's earnings call on Aug 12, 2026, Spero Therapeutics (NASDAQ: SPRO) reported Q2 2026 earnings per share (EPS) of -$0.16, up 433.33% year over year. Total SPRO earnings for the quarter were -$9.55 million. In the same quarter last year, Spero Therapeutics's earnings per share (EPS) was -$0.03.

If you're new to stock investing, here's how to buy Spero Therapeutics stock.

When does Spero Therapeutics report earnings?

The next SPRO earnings date is Nov 12, 2026. Add SPRO to your watchlist to be reminded of Spero Therapeutics's next earnings date.

Is Spero Therapeutics profitable or losing money?

As of the last Spero Therapeutics earnings report, Spero Therapeutics is currently profitable. Spero Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $7.38 million, a 113.77% decrease year over year.

What was SPRO's earnings growth in the past year?

As of Spero Therapeutics's earnings date in Aug 12, 2026, Spero Therapeutics's earnings has grown year over year. SPRO earnings in the past year totalled $7.38 million.

What are Spero Therapeutics's earnings expectations?

The current EPS estimate for Spero Therapeutics's earnings report in Nov 12, 2026 is -$0.14.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.